{"groups":[{"description":"Phase I patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1\n* 10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"FG000","title":"Phase I"},{"description":"Phase II patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* 0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"FG001","title":"Phase II"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"8"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Phase I of this study opened 10/20/2004 and accrued 30 patients before closing 10/29/2007. Eight patients were accrued to the Phase II portion at the maximum tolerated dose established in Phase I."}